# Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement

Study · id `cardio:ct-nct02390102` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02390102](<https://clinicaltrials.gov/study/NCT02390102>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02390102

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 117 participants.

## Technical summary

Registry record NCT02390102. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (actual); primary completion 2015-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 117 participants (enrolled count; ClinicalTrials.gov record NCT02390102, source copy `cardio:ctgov-nct02390102-2018-07-17`, retrieved 2026-10-26)
- Started: 2012-06 (actual) (ClinicalTrials.gov record NCT02390102, source copy `cardio:ctgov-nct02390102-2018-07-17`, retrieved 2026-10-26)
- Primary completion: 2015-06 (actual) (ClinicalTrials.gov record NCT02390102, source copy `cardio:ctgov-nct02390102-2018-07-17`, retrieved 2026-10-26)
- Completion: 2016-06 (actual) (ClinicalTrials.gov record NCT02390102, source copy `cardio:ctgov-nct02390102-2018-07-17`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02390102, source copy `cardio:ctgov-nct02390102-2018-07-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02390102-2018-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement
- Acronym: EPICURE
- Condition: Anemia
- Condition: Aortic Stenosis
- Intervention (Drug): Erythropoietin
- Intervention (Drug): Placebo
- Lead sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (`cardio:org-centre-de-recherche-de-l-institut-universitaire-de-17cd1e`)

## Provenance

Content hash: 8fb466f1675da2e1007cb51f7da5a8fc99642d678114363267aed4de72cf4515
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
